Olatec Therapeutics

Executive Summary

Olatec Therapeutics is a clinical-stage biopharmaceutical company pioneering oral NLRP3 inflammasome antagonists for inflammatory diseases. Its lead candidate, dapansutrile (OLT1177), is a selective inhibitor of the NLRP3 inflammasome, reducing IL-1β and IL-18 production. The company targets acute and chronic conditions such as osteoarthritis, gout, and cardiovascular diseases. Founded in 2006 and privately held, Olatec has advanced dapansutrile through Phase 2 trials, demonstrating favorable safety and efficacy signals. The platform's versatility supports a broad pipeline, positioning Olatec as a leader in targeting the NLRP3 pathway, a validated mechanism in inflammation. With no approved NLRP3-targeted oral therapies, Olatec has a first-mover advantage if clinical success continues.

Upcoming Catalysts (preview)

• H1 2027Phase 2b data readout for dapansutrile in osteoarthritis60% success
• Q4 2026Initiation of Phase 2b trial in acute gout70% success
• H2 2026Strategic partnership or licensing deal for dapansutrile50% success